Abstract:Subunit vaccines have the potential advantage to boost Mycobacterium bovis Bacillus Calmette-Guerin (BCG)-primed immunity in adults. However, most candidates are antigens highly expressed in replicating bacilli but not in dormant or persisting bacilli, which exist during Mycobacterium tuberculosis infection. We constructed M. tuberculosis fusion protein Ag85B-Mpt64(190-198)-HspX (AMH) and Ag85B-Mpt64(190-198)-Mtb8.4 (AMM), which consist of Ag85B, the 190-198 peptide of Mpt64, HspX (Rv2031c) and Mtb8.4 (Rv1174c), respectively. AMH and/or AMM were mixed with adjuvants composed of dimethyl-dioctyldecyl ammonium bromide and BCG polysaccharide nucleic acid (DDA-BCG PSN) to construct subunit vaccines. Mice were immunized thrice with Ag85B, AMH and AMM vaccines and the immunogenicity of the fusion protein vaccines was determined. Then, mice were primed with BCG and boosted twice with Ag85B, AMH, AMM and AMM + AMH vaccines, respectively, followed by challenging with M. tuberculosis virulent strain H37Rv, and the immune responses and protective effects were measured. It was found that mice immunized with AMH vaccine generated high levels of antigen-specific cell-mediated responses. Compared with the group injected only with BCG, the mice boosted with AMM, AMH and AMM + AMH produced higher levels of Ag85B-specific IgG1 and IgG2a and IFN-gamma-secreting T cells upon Ag85B and Mycobacterium tuberculosis purified protein derivative (PPD) stimulation. It is interesting that only mice boosted with AMM + AMH had significantly lower bacterial count in the lungs than those receiving BCG, whereas mice boosted with AMH or AMM did not. The results suggest that AMH consisting of HspX, the antigen highly expressed in dormant bacilli, could be combined with antigens from replicating bacilli to enhance BCG primed immunity so as to provide better protection against both growing and non-growing bacteria that occur during the infection process.

BCG-booster vaccination with HSP90-ESAT-6-HspX-RipA multivalent subunit vaccine confers durable protection against hypervirulent Mtb in mice

Repeated Aerosolized-Boosting with Gamma-Irradiated Mycobacterium bovis BCG Confers Improved Pulmonary Protection against the Hypervirulent Mycobacterium tuberculosis Strain HN878 in Mice

A multistage protein subunit vaccine as BCG-booster confers protection against Mycobacterium tuberculosis infection in murine models

Recombinant BCG vaccine expressing multistage antigens of Mycobacterium tuberculosis provides long-term immunity against tuberculosis in BALB/c mice

A Multistage Protein Subunit Vaccine As Bcg-Booster Confers Protection Against M Ycobacterium Tuberculosis Infection in Murine Models

Recombinant BCG Prime and PPE Protein Boost Provides Potent Protection Against Acute Mycobacterium Tuberculosis Infection in Mice

Rv2299c, a novel dendritic cell-activating antigen of Mycobacterium tuberculosis, fused-ESAT-6 subunit vaccine confers improved and durable protection against the hypervirulent strain HN878 in mice

Immunogenicity and Protective Efficacy of a Fusion Protein Vaccine Consisting of Antigen Ag85B and HspX Against Mycobacterium Tuberculosis Infection in Mice

HBHA vaccination may require both Th1 and Th17 immune responses to protect mice against tuberculosis

Enhanced Protective Efficacy Against Mycobacterium Tuberculosis Afforded by BCG Prime‐dna Boost Regimen in an Early Challenge Mouse Model is Associated with Increased Splenic Interleukin‐2‐producing CD4 T‐cell Frequency Post‐vaccination

A Heterologous DNA Priming-Mycobacterium Bovis BCG Boosting Immunization Strategy Using Mycobacterial Hsp70, Hsp65, and Apa Antigens Improves Protection Against Tuberculosis in Mice.

Novel Recombinant Bcg Coexpressing Ag85b, Esat-6 and Mouse Tnf-Alpha Induces Significantly Enhanced Cellular Immune and Antibody Responses in C57bl/6 Mice

Heterologous Boosting with Recombinant Vsv-846 in Bcg-Primed Mice Confers Improved Protection Against Mycobacterium Infection

Recombinant Bcg Coexpressing Ag85b, Esat-6 and Rv3620c Elicits Specific Th1 Immune Responses in C57bl/6 Mice

Evaluation Of A New Recombinant Bcg Which Contains Mycobacterial Antigen Ag85b-Mpt64(190-198)-Mtb8.4 In C57/Bl6 Mice

Novel Recombinant Bcg Coexpressing Ag85b, Esat-6 And Rv2608 Elicits Significantly Enhanced Cellular Immune And Antibody Responses In C57bl/6 Mice

Immunogenic profiling of Mycobacterium tuberculosis Rv1513 reveals its ability to switch on Th1 based immunity

Boosting BCG-primed Mice with Chimeric DNA Vaccine HG856A Induces Potent Multifunctional T Cell Responses and Enhanced Protection Against Mycobacterium Tuberculosis

Subunit Vaccine Consisting Of Multi-Stage Antigens Has High Protective Efficacy Against Mycobacterium Tuberculosis Infection In Mice

Immunogenicity and protective efficacy of heterologous prime-boost regimens with mycobacterial vaccines and recombinant adenovirus- and poxvirus-vectored vaccines against murine tuberculosis.

Prime-boost vaccination with Bacillus Calmette Guerin and a recombinant adenovirus co-expressing CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium tuberculosis induces robust antigen-specific immune responses in mice.